Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate

P. C. Walsh, P. K. Siiteri

Research output: Contribution to journalArticlepeer-review

Abstract

Spironolactone, an inhibitor of androgen synthesis, has been administered to castrated men with metastatic carcinoma of the prostate. Plasma levels of testosterone, androstenedione and dehydroepiandrosterone were significantly decreased. These data indicated that spironolactone suppresses adrenal androgen production and suggest that it may be of benefit in the treatment of orchiectomized patients with advanced carcinoma of the prostate.

Original languageEnglish (US)
Pages (from-to)254-256
Number of pages3
JournalJournal of Urology
Volume114
Issue number2
DOIs
StatePublished - Jan 1 1975
Externally publishedYes

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate'. Together they form a unique fingerprint.

Cite this